Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03963414 2023-08-28

A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC

Phase 1 Terminated

1 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Phase 1 Completed

32 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03085849 2018-12-10

SGI-110 Plus Durvalumab/Tremelimumab in SCLC

Phase 1 Completed

2 enrolled

Thoracic

Small Cell Lung Carcinoma

Clinical Trials

IMFINZI-subQ

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

(DeLLphi-310)

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

DAREONᵀᴹ-8

CLOVER

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

SGI-110 Plus Durvalumab/Tremelimumab in SCLC